|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Acebutolol#Patient Counseling Information]] |
| {{Acebutolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Patient Counseling Information==
| |
| | |
| Patients, especially those with evidence of coronary artery disease, should be warned against interruption or discontinuation of Sectral therapy without a physician’s supervision. Although cardiac failure rarely occurs in properly selected patients, those being treated with β-adrenergic blocking agents should be advised to consult a physician if they develop signs or symptoms suggestive of impending [[CHF]], or unexplained respiratory symptoms.
| |
| | |
| Patients should also be warned of possible severe hypertensive reactions from concomitant use of α-adrenergic stimulants, such as the nasal decongestants commonly used in OTC cold preparations and nasal drops.
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SECTRAL (ACEBUTOLOL HYDROCHLORIDE) CAPSULE [PROMIUS PHARMA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7eee95bf-0452-4d6e-9712-33403768695a | publisher = | date = | accessdate = 3 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |